Moreover, the therapeutic promise of targeting the NLRP3 inflammasome also extends to oncology; studies show that, depending on the tumour environment, altering this pathway can either promote or hinder the proliferation of cancer cells (Missiroli et al. 2021). This evidence concerns the gene NLRP3 and cancer.